| Year |
Citation |
Score |
| 2019 |
Bouchet S, Linot C, Ruzic D, Agbaba D, Fouchaq B, Roche J, Nikolic K, Blanquart C, Bertrand P. Extending Cross Metathesis To Identify Selective HDAC Inhibitors: Synthesis, Biological Activities, and Modeling. Acs Medicinal Chemistry Letters. 10: 863-868. PMID 31223439 DOI: 10.1021/Acsmedchemlett.8B00440 |
0.453 |
|
| 2018 |
Roche J. Erratum: Roche, J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers, 2018, 10, 52. Cancers. 10. PMID 29562660 DOI: 10.3390/Cancers10030079 |
0.39 |
|
| 2018 |
Roche J. The Epithelial-to-Mesenchymal Transition in Cancer. Cancers. 10. PMID 29462906 DOI: 10.3390/Cancers10020052 |
0.325 |
|
| 2017 |
Evanno E, Godet J, Piccirilli N, Guilhot J, Milin S, Gombert JM, Fouchaq B, Roche J. Tri-methylation of H3K79 is decreased in TGF-β1-induced epithelial-to-mesenchymal transition in lung cancer. Clinical Epigenetics. 9: 80. PMID 28804523 DOI: 10.1186/S13148-017-0380-0 |
0.502 |
|
| 2017 |
Roche J, Gemmill RM, Drabkin HA. Epigenetic Regulation of the Epithelial to Mesenchymal Transition in Lung Cancer. Cancers. 9. PMID 28672805 DOI: 10.3390/Cancers9070072 |
0.509 |
|
| 2017 |
Dimou A, Dincman T, Evanno E, Gemmill RM, Roche J, Drabkin HA. Epigenetics during EMT in lung cancer: EZH2 as a potential therapeutic target Cancer Treatment and Research. 12: 40-48. DOI: 10.1016/J.Ctarc.2017.06.003 |
0.449 |
|
| 2016 |
Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Erratum: Roche, J. et al. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers, 2013, 5, 334-356. Cancers. 8. PMID 27983677 DOI: 10.3390/Cancers8120114 |
0.759 |
|
| 2016 |
Yoshida T, Song L, Bai Y, Kinose F, Li J, Ohaegbulam KC, Muñoz-Antonia T, Qu X, Eschrich S, Uramoto H, Tanaka F, Nasarre P, Gemmill RM, Roche J, Drabkin HA, et al. ZEB1 Mediates Acquired Resistance to the Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer. Plos One. 11: e0147344. PMID 26789630 DOI: 10.1371/Journal.Pone.0147344 |
0.759 |
|
| 2013 |
Roche J, Nasarre P, Gemmill R, Baldys A, Pontis J, Korch C, Guilhot J, Ait-Si-Ali S, Drabkin H. Global Decrease of Histone H3K27 Acetylation in ZEB1-Induced Epithelial to Mesenchymal Transition in Lung Cancer Cells. Cancers. 5: 334-56. PMID 24216980 DOI: 10.3390/Cancers5020334 |
0.806 |
|
| 2013 |
Nasarre P, Gemmill RM, Potiron VA, Roche J, Lu X, Barón AE, Korch C, Garrett-Mayer E, Lagana A, Howe PH, Drabkin HA. Neuropilin-2 Is upregulated in lung cancer cells during TGF-β1-induced epithelial-mesenchymal transition. Cancer Research. 73: 7111-21. PMID 24121493 DOI: 10.1158/0008-5472.Can-13-1755 |
0.813 |
|
| 2012 |
Nasarre P, Roche J, Potiron VA, Nair-Menon J, Gemmill RM, Drabkin HA. Abstract 2416: Neuropilin-2 is upregulated during EMT in lung cancer Cancer Research. 72: 2416-2416. DOI: 10.1158/1538-7445.Am2012-2416 |
0.821 |
|
| 2011 |
Thomas M, Clarhaut J, Strale PO, Tranoy-Opalinski I, Roche J, Papot S. A galactosidase-responsive "trojan horse" for the selective targeting of folate receptor-positive tumor cells. Chemmedchem. 6: 1006-10. PMID 21442760 DOI: 10.1002/Cmdc.201100114 |
0.69 |
|
| 2011 |
Gemmill RM, Roche J, Potiron VA, Nasarre P, Mitas M, Coldren CD, Helfrich BA, Garrett-Mayer E, Bunn PA, Drabkin HA. ZEB1-responsive genes in non-small cell lung cancer. Cancer Letters. 300: 66-78. PMID 20980099 DOI: 10.1016/J.Canlet.2010.09.007 |
0.817 |
|
| 2011 |
Potiron V, Drabkin H, Roche J. SEMA3F (sema domain, immunoglobulin domain (Ig), short basic domain, secreted, (semaphorin) 3F) Atlas of Genetics and Cytogenetics in Oncology and Haematology. DOI: 10.4267/2042/44387 |
0.645 |
|
| 2010 |
Nasarre P, Potiron V, Drabkin H, Roche J. Guidance molecules in lung cancer. Cell Adhesion & Migration. 4: 130-45. PMID 20139699 DOI: 10.4161/Cam.4.1.10882 |
0.815 |
|
| 2010 |
Roche J, Nasarre P, Potiron V, Nair-Menon J, Gemmill R, Drabkin H. Abstract 4969: Neuropilin-2 is downregulated by Snail during EMT in lung cancer Cancer Research. 70: 4969-4969. DOI: 10.1158/1538-7445.Am10-4969 |
0.837 |
|
| 2009 |
Charrier C, Clarhaut J, Gesson JP, Estiu G, Wiest O, Roche J, Bertrand P. Synthesis and modeling of new benzofuranone histone deacetylase inhibitors that stimulate tumor suppressor gene expression. Journal of Medicinal Chemistry. 52: 3112-5. PMID 19385600 DOI: 10.1021/Jm9002439 |
0.756 |
|
| 2009 |
Clarhaut J, Gemmill RM, Potiron VA, Ait-Si-Ali S, Imbert J, Drabkin HA, Roche J. ZEB-1, a repressor of the semaphorin 3F tumor suppressor gene in lung cancer cells. Neoplasia (New York, N.Y.). 11: 157-66. PMID 19177200 DOI: 10.1593/Neo.81074 |
0.843 |
|
| 2009 |
Potiron VA, Roche J, Drabkin HA. Semaphorins and their receptors in lung cancer. Cancer Letters. 273: 1-14. PMID 18625544 DOI: 10.1016/J.Canlet.2008.05.032 |
0.776 |
|
| 2009 |
Charrier C, Roche J, Gesson J, Bertrand P. Biological activities of substituted trichostatic acid derivatives Journal of Chemical Sciences. 121: 471-479. DOI: 10.1007/S12039-009-0056-1 |
0.369 |
|
| 2008 |
Karayan-Tapon L, Wager M, Guilhot J, Levillain P, Marquant C, Clarhaut J, Potiron V, Roche J. Semaphorin, neuropilin and VEGF expression in glial tumours: SEMA3G, a prognostic marker? British Journal of Cancer. 99: 1153-60. PMID 18781179 DOI: 10.1038/Sj.Bjc.6604641 |
0.78 |
|
| 2008 |
Thomas M, Clarhaut J, Tranoy-Opalinski I, Gesson JP, Roche J, Papot S. Synthesis and biological evaluation of glucuronide prodrugs of the histone deacetylase inhibitor CI-994 for application in selective cancer chemotherapy. Bioorganic & Medicinal Chemistry. 16: 8109-16. PMID 18692397 DOI: 10.1016/J.Bmc.2008.07.048 |
0.723 |
|
| 2007 |
Charrier C, Roche J, Gesson JP, Bertrand P. Antiproliferative activities of a library of hybrids between indanones and HDAC inhibitor SAHA and MS-275 analogues. Bioorganic & Medicinal Chemistry Letters. 17: 6142-6. PMID 17897824 DOI: 10.1016/J.Bmcl.2007.09.041 |
0.408 |
|
| 2007 |
Potiron VA, Sharma G, Nasarre P, Clarhaut JA, Augustin HG, Gemmill RM, Roche J, Drabkin HA. Semaphorin SEMA3F affects multiple signaling pathways in lung cancer cells. Cancer Research. 67: 8708-15. PMID 17875711 DOI: 10.1158/0008-5472.Can-06-3612 |
0.799 |
|
| 2007 |
Loudni L, Roche J, Potiron V, Clarhaut J, Bachmann C, Gesson JP, Tranoy-Opalinski I. Design, synthesis and biological evaluation of 1,4-benzodiazepine-2,5-dione-based HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 17: 4819-23. PMID 17624773 DOI: 10.1016/J.Bmcl.2007.06.067 |
0.783 |
|
| 2007 |
Potiron V, Nasarre P, Roche J, Healy C, Boumsell L. Semaphorin signaling in the immune system. Advances in Experimental Medicine and Biology. 600: 132-44. PMID 17607952 DOI: 10.1007/978-0-387-70956-7_11 |
0.766 |
|
| 2006 |
Clarhaut J, Roche J, Drabkin HA. Semaphorins in lung cancer. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. 1: 203-4. PMID 17409857 DOI: 10.1016/S1556-0864(15)31568-9 |
0.773 |
|
| 2006 |
Charrier C, Bertrand P, Gesson JP, Roche J. Synthesis of rigid trichostatin A analogs as HDAC inhibitors. Bioorganic & Medicinal Chemistry Letters. 16: 5339-44. PMID 16904890 DOI: 10.1016/J.Bmcl.2006.07.080 |
0.427 |
|
| 2005 |
Kusy S, Potiron V, Zeng C, Franklin W, Brambilla E, Minna J, Drabkin HA, Roche J. Promoter characterization of Semaphorin SEMA3F, a tumor suppressor gene. Biochimica Et Biophysica Acta. 1730: 66-76. PMID 16005989 DOI: 10.1016/J.Bbaexp.2005.05.008 |
0.73 |
|
| 2005 |
Nasarre P, Constantin B, Drabkin HA, Roche J. [Semaphorins and cancers : an up 'dating']. Medecine Sciences : M/S. 21: 641-7. PMID 15985208 DOI: 10.1051/Medsci/2005216-7641 |
0.805 |
|
| 2005 |
Kusy S, Nasarre P, Chan D, Potiron V, Meyronet D, Gemmill RM, Constantin B, Drabkin HA, Roche J. Selective suppression of in vivo tumorigenicity by semaphorin SEMA3F in lung cancer cells. Neoplasia (New York, N.Y.). 7: 457-65. PMID 15967098 DOI: 10.1593/Neo.04721 |
0.813 |
|
| 2005 |
Potiron V, Roche J. Class 3 semaphorin signaling: the end of a dogma. Science's Stke : Signal Transduction Knowledge Environment. 2005: pe24. PMID 15914725 DOI: 10.1126/Stke.2852005Pe24 |
0.705 |
|
| 2005 |
Nasarre P, Kusy S, Constantin B, Castellani V, Drabkin HA, Bagnard D, Roche J. Semaphorin SEMA3F has a repulsing activity on breast cancer cells and inhibits E-cadherin-mediated cell adhesion. Neoplasia (New York, N.Y.). 7: 180-9. PMID 15802023 DOI: 10.1593/Neo.04481 |
0.825 |
|
| 2005 |
Potiron V, Kusy S, Nasarre P, Chan D, Roche J, Drabkin H. PD-019 SEMA3F inhibits tumorigenesis by selective lung cancer cell lines Lung Cancer. 49. DOI: 10.1016/S0169-5002(05)80352-6 |
0.435 |
|
| 2004 |
Kusy S, Larsen CJ, Roche J. p14ARF, p15INK4b and p16INK4a methylation status in chronic myelogenous leukemia. Leukemia & Lymphoma. 45: 1989-94. PMID 15370242 DOI: 10.1080/10428190410001714025 |
0.333 |
|
| 2004 |
Roche J, Zeng C, Barón A, Gadgil S, Gemmill RM, Tigaud I, Thomas X, Drabkin HA. Hox expression in AML identifies a distinct subset of patients with intermediate cytogenetics. Leukemia. 18: 1059-63. PMID 15085154 DOI: 10.1038/Sj.Leu.2403366 |
0.309 |
|
| 2003 |
Roche J, Drabkin HA. The role of semaphorins in lung cancer. Clinical Lung Cancer. 3: 145-50. PMID 14659031 DOI: 10.3816/Clc.2001.N.026 |
0.566 |
|
| 2003 |
Kusy S, Funkelstein L, Bourgais D, Drabkin H, Rougon G, Roche J, Castellani V. Redundant functions but temporal and regional regulation of two alternatively spliced isoforms of semaphorin 3F in the nervous system. Molecular and Cellular Neurosciences. 24: 409-18. PMID 14572462 DOI: 10.1016/S1044-7431(03)00197-0 |
0.379 |
|
| 2003 |
Ohira T, Gemmill RM, Ferguson K, Kusy S, Roche J, Brambilla E, Zeng C, Baron A, Bemis L, Erickson P, Wilder E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, et al. WNT7a induces E-cadherin in lung cancer cells. Proceedings of the National Academy of Sciences of the United States of America. 100: 10429-34. PMID 12937339 DOI: 10.1073/Pnas.1734137100 |
0.474 |
|
| 2003 |
Lantuéjoul S, Constantin B, Drabkin H, Brambilla C, Roche J, Brambilla E. Expression of VEGF, semaphorin SEMA3F, and their common receptors neuropilins NP1 and NP2 in preinvasive bronchial lesions, lung tumours, and cell lines. The Journal of Pathology. 200: 336-47. PMID 12845630 DOI: 10.1002/Path.1367 |
0.676 |
|
| 2003 |
Nasarre P, Constantin B, Rouhaud L, Harnois T, Raymond G, Drabkin HA, Bourmeyster N, Roche J. Semaphorin SEMA3F and VEGF have opposing effects on cell attachment and spreading. Neoplasia (New York, N.Y.). 5: 83-92. PMID 12659673 DOI: 10.1016/S1476-5586(03)80020-9 |
0.812 |
|
| 2003 |
Ohira T, Gemmill RM, Roche J, Brambilla E, Rustgi A, Kitajewski J, Gabrielson E, Bremnes R, Franklin W, Drabkin HA. O-135 WNT7a induces E-cadherin in lung cancer Lung Cancer. 41. DOI: 10.1016/S0169-5002(03)91793-4 |
0.422 |
|
| 2002 |
Roche J, Drabkin H, Brambilla E. Neuropilin and its ligands in normal lung and cancer. Advances in Experimental Medicine and Biology. 515: 103-14. PMID 12613547 DOI: 10.1007/978-1-4615-0119-0_9 |
0.549 |
|
| 2001 |
Tomizawa Y, Sekido Y, Kondo M, Gao B, Yokota J, Roche J, Drabkin H, Lerman MI, Gazdar AF, Minna JD. Inhibition of lung cancer cell growth and induction of apoptosis after reexpression of 3p21.3 candidate tumor suppressor gene SEMA3B. Proceedings of the National Academy of Sciences of the United States of America. 98: 13954-9. PMID 11717452 DOI: 10.1073/Pnas.231490898 |
0.569 |
|
| 2001 |
Calvo R, West J, Franklin W, Erickson P, Bemis L, Li E, Helfrich B, Bunn P, Roche J, Brambilla E, Rosell R, Gemmill RM, Drabkin HA. Altered HOX and WNT7A expression in human lung cancer. Proceedings of the National Academy of Sciences of the United States of America. 97: 12776-81. PMID 11070089 DOI: 10.1073/pnas.97.23.12776 |
0.486 |
|
| 2000 |
Brambilla E, Constantin B, Drabkin H, Roche J. Semaphorin SEMA3F localization in malignant human lung and cell lines: A suggested role in cell adhesion and cell migration. The American Journal of Pathology. 156: 939-50. PMID 10702410 DOI: 10.1016/S0002-9440(10)64962-0 |
0.753 |
|
| 1999 |
Hirsch E, Hu LJ, Prigent A, Constantin B, Agid Y, Drabkin H, Roche J. Distribution of semaphorin IV in adult human brain. Brain Research. 823: 67-79. PMID 10095013 DOI: 10.1016/S0006-8993(99)01103-8 |
0.674 |
|
| 1997 |
Boldog F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Waggoner B, Lundstrom R, Jacobson J, Mullokandov MR, Klinger H, Drabkin HA. Chromosome 3p14 homozygous deletions and sequence analysis of FRA3B. Human Molecular Genetics. 6: 193-203. PMID 9063739 DOI: 10.1093/Hmg/6.2.193 |
0.343 |
|
| 1997 |
Boldog F, Gemmill RM, West J, Robinson M, Robinson L, Li E, Roche J, Todd S, Jacobson J, Klinger H, Drabkin HA. 549 3P14 Homozygous deletions in carcinomas of lung, breast, colon and cervix and sequence analysis of FRA3B Lung Cancer. 18: 141. DOI: 10.1016/S0169-5002(97)89929-1 |
0.34 |
|
| 1995 |
Todd S, Roche J, Hahner L, Bolin R, Drabkin HA, Gemmill RM. YAC contigs covering an 8-megabase region of 3p deleted in the small-cell lung cancer cell line U2020 Genomics. 25: 19-28. PMID 7774917 DOI: 10.1016/0888-7543(95)80105-U |
0.455 |
|
| Show low-probability matches. |